These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 24779206)

  • 21. [Orphan drugs: some legal, ethical and economics aspects].
    Pabst JY
    Rev Epidemiol Sante Publique; 2001 Sep; 49(4):387-96. PubMed ID: 11567205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU.
    Joppi R; Bertele' V; Garattini S
    Eur J Clin Pharmacol; 2013 Apr; 69(4):1009-24. PubMed ID: 23090701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative analysis of the scope of European Union paediatric investigation plans with corresponding orphan designations.
    Ecker A; Mariz S; Naumann-Winter F; Norga K; Barisic I; Girard T; Tomasi P; Mentzer D; Sepodes B
    Arch Dis Child; 2018 May; 103(5):427-430. PubMed ID: 29089318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
    Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
    Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EU to review rare disease drugs market exclusivity.
    Sheridan C
    Nat Biotechnol; 2004 Sep; 22(9):1061. PubMed ID: 15340455
    [No Abstract]   [Full Text] [Related]  

  • 26. Legal assessment of current situation on orphan patients in Lithuania.
    Spokiene I
    Medicina (Kaunas); 2008; 44(8):571-6. PubMed ID: 18791333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A regulatory overview about rare diseases.
    Llinares J
    Adv Exp Med Biol; 2010; 686():193-207. PubMed ID: 20824447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The legal imperative for treating rare disorders.
    Hyry HI; Roos JC; Manuel J; Cox TM
    Orphanet J Rare Dis; 2013 Sep; 8():135. PubMed ID: 24010951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
    Pariser AR; Xu K; Milto J; Coté TR
    Discov Med; 2011 Apr; 11(59):367-75. PubMed ID: 21524390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulations applicable to plant food supplements and related products in the European Union.
    Silano V; Coppens P; Larrañaga-Guetaria A; Minghetti P; Roth-Ehrang R
    Food Funct; 2011 Dec; 2(12):710-9. PubMed ID: 21997496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Creating conditions for the success of the French industrial advanced therapy sector.
    Lirsac PN; Blin O; Magalon J; ; Angot P; de Barbeyrac E; Bilbault P; Bourg E; Damour O; Faure P; Ferry N; Garbil B; Larghero J; Nguon M; Pattou F; Thumelin S; Yates F
    Therapie; 2015; 70(1):69-94. PubMed ID: 25747840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evolving prevalence of haematological malignancies in orphan designation procedures in the European Union.
    Polsinelli B; Tsigkos S; Naumann-Winter F; Mariz S; Sepodes B
    Orphanet J Rare Dis; 2017 Jan; 12(1):17. PubMed ID: 28109318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Orphan drugs].
    Kolár J; Chalabala M; Srámková H
    Ceska Slov Farm; 2001 Mar; 50(2):59-65. PubMed ID: 11288591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rare diseases and orphan drugs.
    Taruscio D; Capozzoli F; Frank C
    Ann Ist Super Sanita; 2011; 47(1):83-93. PubMed ID: 21430345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Marketing authorization of veterinary medicinal products in Poland.
    Sztabińska-Koncka H; Lewicki J
    Regul Toxicol Pharmacol; 1997 Aug; 26(1 Pt 1):129-33. PubMed ID: 9339489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of immunological veterinary medicinal products in the European Union.
    Brunko P
    Rev Sci Tech; 1995 Dec; 14(4):1133-41. PubMed ID: 8639951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The problem of orphan drugs.
    Ferner RE; Hughes DA
    BMJ; 2010 Nov; 341():c6456. PubMed ID: 21081597
    [No Abstract]   [Full Text] [Related]  

  • 38. [The use of nanotechnology in medicinal products in the light of European Union law].
    Jurewicz M
    Pol Merkur Lekarski; 2014 Dec; 37(222):369-72. PubMed ID: 25715580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Removal of the EMA orphan designation upon request of the sponsor: cui prodest?
    Montanaro N; Bonaldo G; Motola D
    Eur J Clin Pharmacol; 2021 Jul; 77(7):1057-1063. PubMed ID: 33501508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EU adopts legislation to promote drug development for rare diseases.
    Whyte B
    Bull World Health Organ; 2000; 78(5):711. PubMed ID: 10859868
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.